RECCE PHARMACEUTICALS LTD — Director's Dealing 2019

Aug 7, 2019

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity Recce Pharmaceuticals Ltd ( Company ) ACN 124 849 065

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Michele Keryn Dilizia
Date of last notice	16 February 2016

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Direct Interest
Nature of indirect interest	N/A
(including registered holder)
Note: Provide details of the circumstances giving rise to the relevant
interest.
Date of change	2 August 2019
	5 August 2019
	6 August 2019
	7 August 2019
No. of securities held prior to change	2,886,061 fully paid ordinary shares
	577,212 Class B Performance Shares
	(and any fully paid ordinary shares
	issued on conversion)
	577,212 Class C Performance Shares
	(and any fully paid ordinary shares
	issued on conversion)
	577,212 Class D Performance Shares
	(and any fully paid ordinary shares
	issued on conversion)
Class	Fully paid ordinary shares

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Number acquired	Nil
Number disposed	277,000 fully paid ordinary shares
Value/ConsiderationNote: If consideration is non-cash, provide details and estimatedvaluation	$60,180
No. of securities held after change	2,609,061 fully paid ordinary shares577,212 Class B Performance Shares(and any fully paid ordinary sharesissued on conversion)577,212 Class C Performance Shares(and any fully paid ordinary sharesissued on conversion)577,212 Class D Performance Shares(and any fully paid ordinary sharesissued on conversion)
Nature of changeExample: on-market trade, off-market trade, exercise of options,issue of securities under dividend reinvestment plan, participation inbuy-back	On-market sale of 277,000 fully paidordinary shares

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder(if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior tochangeNote: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/ConsiderationNote: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

Part 3 – +Closed period

Part 3 – +Closed period
Were the interests in the securities or contracts detailed abovetraded during a+closed period where prior written clearance wasrequired?	No
If so, was prior written clearance provided to allow the trade toproceed during this period?	N/A
If prior written clearance was provided, on what date was thisprovided?	N/A

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 3